View in EDS

Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform.

Saved in:
Bibliographic Details
Title: Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform.
Authors: Zhang Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Li Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ritter J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Brea EJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Mahadevan NR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Dillon DA; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Park SR; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA, USA., Liu EM; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA, USA., Tolstorukov MY; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA, USA., McGourty WE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lizotte P; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Ivanova EV; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Fahey C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Haratani K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Thai TC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Soroko KM; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Kivlehan S; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Smith EL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Gokhale PC; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Paweletz CP; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Barbie TU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Division of Breast Surgery, Department of Surgery, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. Electronic address: tbarbie@bwh.harvard.edu.
Source: Cell reports. Medicine [Cell Rep Med] 2025 Jul 15; Vol. 6 (7), pp. 102198. Date of Electronic Publication: 2025 Jun 20.
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40543510
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhang+Y%22">Zhang Y</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Li+Z%22">Li Z</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ritter+J%22">Ritter J</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Brea+EJ%22">Brea EJ</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Mahadevan+NR%22">Mahadevan NR</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Dillon+DA%22">Dillon DA</searchLink>; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Park+SR%22">Park SR</searchLink>; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Liu+EM%22">Liu EM</searchLink>; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Tolstorukov+MY%22">Tolstorukov MY</searchLink>; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22McGourty+WE%22">McGourty WE</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Lizotte+P%22">Lizotte P</searchLink>; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ivanova+EV%22">Ivanova EV</searchLink>; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Fahey+C%22">Fahey C</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Haratani+K%22">Haratani K</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Thai+TC%22">Thai TC</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Soroko+KM%22">Soroko KM</searchLink>; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Kivlehan+S%22">Kivlehan S</searchLink>; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Smith+EL%22">Smith EL</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Gokhale+PC%22">Gokhale PC</searchLink>; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Paweletz+CP%22">Paweletz CP</searchLink>; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Barbie+DA%22">Barbie DA</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Barbie+TU%22">Barbie TU</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Division of Breast Surgery, Department of Surgery, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA; Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. Electronic address: tbarbie@bwh.harvard.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101766894%22">Cell reports. Medicine</searchLink> [Cell Rep Med] 2025 Jul 15; Vol. 6 (7), pp. 102198. <i>Date of Electronic Publication: </i>2025 Jun 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101766894 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-3791 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226663791%22">26663791 </searchLink><i>NLM ISO Abbreviation: </i>Cell Rep Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40543510
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.xcrm.2025.102198
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 102198
    Titles:
      – TitleFull: Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhang Y
      – PersonEntity:
          Name:
            NameFull: Li Z
      – PersonEntity:
          Name:
            NameFull: Ritter J
      – PersonEntity:
          Name:
            NameFull: Brea EJ
      – PersonEntity:
          Name:
            NameFull: Mahadevan NR
      – PersonEntity:
          Name:
            NameFull: Dillon DA
      – PersonEntity:
          Name:
            NameFull: Park SR
      – PersonEntity:
          Name:
            NameFull: Liu EM
      – PersonEntity:
          Name:
            NameFull: Tolstorukov MY
      – PersonEntity:
          Name:
            NameFull: McGourty WE
      – PersonEntity:
          Name:
            NameFull: Lizotte P
      – PersonEntity:
          Name:
            NameFull: Ivanova EV
      – PersonEntity:
          Name:
            NameFull: Fahey C
      – PersonEntity:
          Name:
            NameFull: Haratani K
      – PersonEntity:
          Name:
            NameFull: Thai TC
      – PersonEntity:
          Name:
            NameFull: Soroko KM
      – PersonEntity:
          Name:
            NameFull: Kivlehan S
      – PersonEntity:
          Name:
            NameFull: Smith EL
      – PersonEntity:
          Name:
            NameFull: Gokhale PC
      – PersonEntity:
          Name:
            NameFull: Paweletz CP
      – PersonEntity:
          Name:
            NameFull: Barbie DA
      – PersonEntity:
          Name:
            NameFull: Barbie TU
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 07
              Text: 2025 Jul 15
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2666-3791
          Numbering:
            – Type: volume
              Value: 6
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Cell reports. Medicine
              Type: main
ResultId 1